Vita Life Sciences (VLS) investor relations material

Opening remarks and agenda

• Meeting opened with confirmation of quorum and introduction of board members and auditor, with online participation enabled for shareholders.

• Shareholders instructed to submit questions via Q&A function, referencing specific resolutions.

• Annual General Meeting held on 28 May 2026, led by the Managing Director.

Financial performance review

• Revenue for FY2025 reached AUD 93.3 million, up 17.3% year-on-year; profit before tax rose 14.1% to AUD 14.4 million.

• Gross profit margin increased by 1.7% to 61%; cash reserves at AUD 35.6 million, equity at AUD 56.2 million, with no bank borrowings.

• Five-year revenue growth of 101% and pre-tax profit growth of 70% highlighted.

• Cash conversion remained strong at 126%; a 2.2 million share buyback was executed.

• Record full-year performance and broad-based growth across core markets; Australia up 8%, Malaysia & Singapore up 35%.

Dividend announcements

• Full-year dividend declared at AUD 0.14 per share, up AUD 0.04 from prior year.

• Sixteen consecutive years of dividend payments, with a 24% CAGR over the past six years.